Androvax, also known as androstenedione:human serum albumin conjugate, is an immunogen and vaccine against androstenedione that is used in veterinary medicine to increase the ovulation rate and number of lambs born to ewes.[1][2][3] It is a conjugate of androstenedione and human serum albumin.[1][3] The drug is marketed in New Zealand.[1][3]

Androvax
Combination of
AndrostendioneAndrostane steroid
Human serum albuminSerum protein
Clinical data
Trade namesAndrovax
Other namesAndrostenedione:human serum albumin conjugate
AHFS/Drugs.comMonograph
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • None

Androvax produces immunity against androstenedione, and the generation of antibodies against androstenedione decreases circulating levels of androstenedione.[1] In addition, since androstenedione is the major precursor of estrogens, estrogen levels are decreased as well.[1] This is thought to result in reduced negative feedback on the hypothalamic-pituitary-gonadal axis and increased gonadotropin secretion, which in turn improves fertility and fecundity.[1]

See also

edit

References

edit
  1. ^ a b c d e f Jindal SK, Sharma MC (2010). Biotechnology in Animal Health and Production. New India Publishing. pp. 77–. ISBN 978-93-80235-35-6.
  2. ^ Reproductive Technologies in Farm Animals. CABI. 2004. pp. 206–. ISBN 978-0-85199-049-1.
  3. ^ a b c "Androvax Label" (PDF). Schering-Plough Animal Health Ltd. MSD Animal Health.